ALGS – aligos therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Aligos Therapeutics (ALGS) is now covered by Westpark Capital. They set a "buy" rating and a $48.00 price target on the stock.
Aligos Therapeutics (ALGS) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Form 8-K Aligos Therapeutics, For: Apr 14
Form 4 Aligos Therapeutics, For: Mar 09 Filed by: Symons Julian A.
Form 4 Aligos Therapeutics, For: Mar 09 Filed by: Aneja Nikhil
Form 4 Aligos Therapeutics, For: Mar 09 Filed by: BLATT LAWRENCE
Form 4 Aligos Therapeutics, For: Mar 09 Filed by: Calhoun Lesley Ann
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.